Figure 4.

Intratumoral administration of Toxoplasma gondii ΔGRA17 inhibits the growth of non-injected (distant) tumors. (A) Schematic of treatment regimen and timeline for mice inoculated with B16-F10, LLC, or MC38 cells. (B) Growth kinetic of injected tumors and distant tumors, and the overall animal survival in a bilateral B16-F10 melanoma mouse model. (C) Representative luminescence images of mice injected with melanoma B16-F10- Luc cells and treated with ΔGRA17 compared with control mice treated with phosphate buffered saline (PBS). (D) Representative photos of injected and distant melanoma tumors. (E) The size of the injected and distant melanoma tumors, corresponding to the mice in (D). (F) Immunohistochemical staining analysis of melanoma malignancy and the corresponding Immunoreactivity Score (IRS) of CD63, S100β, and Ki-67 expression. (G) Tumor size and mouse survival in bilateral LLC tumor model. (H Tumor size and mouse survival in bilateral MC38 tumor model. The survival of tumor-bearing mice was monitored by Kaplan-Meier analysis, and statistical analyses were performed with log-rank test. Data are shown as mean±SD (n=6 mice/group) of three independent experiments; Student’s t-test, *p<0.05, **p<0.01, ***p<0.001, n/s, not significant compared with the indicated control.